Fibrocell brings in $9.9mm through FOPO

Regenerative medicine company Fibrocell Science Inc. (autologous cell and gene therapies focused on skin and connective tissue disorders) netted $9.9mm through the public offering of 7.7mm units (consisting of 7.7mm common shares and five-year warrants to purchase 13.6mm common shares at $0.77) at $0.77 and 5.9mm pre-funded warrants at $0.76. (In addition, there was a partial exercise of the overallotment of warrants to purchase up to 410.6k shares of common stock.) Fibrocell will use the proceeds to advance its pipeline, which includes FCX007 (Phase I/II for recessive dystrophic epidermolysis bullosa) and FCX013 (preclinical for scleroderma). It will also use the funds for continued development of potential candidates under its 2012 collaboration (expanded in 2015) with Intrexon, in which it's using the latter's technology to develop genetically modified fibroblasts for chronic inflammatory and degenerative diseases of the joint. The program, in the research stage, is currently pursuing a gene-therapy for arthritis and related conditions.